Algert Global LLC Increases Stock Holdings in Dyne Therapeutics, Inc. $DYN

Key Points

• Algert Global LLC significantly increased its stake in Dyne Therapeutics by 488.2%, holding 476,007 shares worth approximately $4.98 million after acquiring an additional 395,084 shares in the 1st quarter.
• CEO John Cox bought 100,000 shares at $9.11 each, raising his total ownership to 242,179 shares, marking a 70.33% increase in his stake.
• Analysts have set a consensus price target of $33.80 for Dyne Therapeutics, with a majority rating the stock as a "Moderate Buy." Several firms have recently adjusted their price targets downward.

Algert Global LLC lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 488.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 476,007 shares of the company's stock after acquiring an additional 395,084 shares during the period. Algert Global LLC owned 0.42% of Dyne Therapeutics worth $4,979,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Dyne Therapeutics by 10.5% during the first quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company's stock worth $77,470,000 after acquiring an additional 702,418 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Dyne Therapeutics by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after acquiring an additional 566,146 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $42,408,000. Orbimed Advisors LLC grew its position in shares of Dyne Therapeutics by 73.2% during the fourth quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company's stock worth $28,910,000 after acquiring an additional 518,680 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in shares of Dyne Therapeutics by 3.6% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 932,231 shares of the company's stock worth $21,963,000 after purchasing an additional 32,041 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In other news, CEO John Cox purchased 100,000 shares of the company's stock in a transaction dated Monday, July 14th. The stock was acquired at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the transaction, the chief executive officer directly owned 242,179 shares in the company, valued at $2,206,250.69. This represents a 70.33% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 20.77% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Sanford C. Bernstein assumed coverage on Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price target for the company. HC Wainwright decreased their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Evercore ISI reaffirmed an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Royal Bank Of Canada decreased their price target on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, July 29th. Finally, Stifel Nicolaus decreased their price target on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of "Buy" and an average target price of $33.80.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock traded up $0.36 during midday trading on Friday, reaching $12.58. The company's stock had a trading volume of 2,298,424 shares, compared to its average volume of 3,037,975. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $46.81. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. The stock's 50 day simple moving average is $10.23 and its 200 day simple moving average is $11.16. The firm has a market capitalization of $1.79 billion, a PE ratio of -3.26 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.